108 related articles for article (PubMed ID: 21047106)
21. Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3.
Leffler A; Ahlstedt I; Engberg S; Svensson A; Billger M; Oberg L; Bjursell MK; Lindström E; von Mentzer B
Biochem Pharmacol; 2009 May; 77(9):1522-30. PubMed ID: 19426690
[TBL] [Abstract][Full Text] [Related]
22. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening.
Kiss R; Kiss B; Könczöl A; Szalai F; Jelinek I; László V; Noszál B; Falus A; Keseru GM
J Med Chem; 2008 Jun; 51(11):3145-53. PubMed ID: 18459760
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological characterization of senktide-induced tail whips.
Nordquist RE; Ballard TM; Algeyer B; Pauly-Evers M; Ozmen L; Spooren W
Neuropharmacology; 2010 Jan; 58(1):259-67. PubMed ID: 19540857
[TBL] [Abstract][Full Text] [Related]
24. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
25. First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening.
Jain V; Saravanan P; Arvind A; Mohan CG
Chem Biol Drug Des; 2011 May; 77(5):373-87. PubMed ID: 21284830
[TBL] [Abstract][Full Text] [Related]
26. New quinoline NK3 receptor antagonists with CNS activity.
Smith PW; Wyman PA; Lovell P; Goodacre C; Serafinowska HT; Vong A; Harrington F; Flynn S; Bradley DM; Porter R; Coggon S; Murkitt G; Searle K; Thomas DR; Watson JM; Martin W; Wu Z; Dawson LA
Bioorg Med Chem Lett; 2009 Feb; 19(3):837-40. PubMed ID: 19117759
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and SAR of sulfoxide substituted carboxyquinolines as NK3 receptor antagonists.
Xiong H; Kang J; Woods JM; McCauley JP; Koether GM; Albert JS; Hinkley L; Li Y; Gadient RA; Simpson TR
Bioorg Med Chem Lett; 2011 Mar; 21(6):1896-9. PubMed ID: 21320776
[TBL] [Abstract][Full Text] [Related]
28. Occurrence and pharmacological characterization of four human tachykinin NK2 receptor variants.
Ahlstedt I; Engberg S; Smith J; Perrey C; Moody A; Morten J; Lagerström-Fermér M; Drmota T; von Mentzer B; Påhlman I; Lindström E
Biochem Pharmacol; 2008 Aug; 76(4):476-81. PubMed ID: 18601911
[TBL] [Abstract][Full Text] [Related]
29. Tetrahydroquinoline derivatives as opioid receptor antagonists.
Zhang C; Westaway SM; Speake JD; Bishop MJ; Goetz AS; Carballo LH; Hu M; Epperly AH
Bioorg Med Chem Lett; 2011 Jan; 21(2):670-6. PubMed ID: 21193310
[TBL] [Abstract][Full Text] [Related]
30. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.
Catalioto RM; Criscuoli M; Cucchi P; Giachetti A; Gianotti D; Giuliani S; Lecci A; Lippi A; Patacchini R; Quartara L; Renzetti AR; Tramontana M; Arcamone F; Maggi CA
Br J Pharmacol; 1998 Jan; 123(1):81-91. PubMed ID: 9484857
[TBL] [Abstract][Full Text] [Related]
31. Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligands.
Peters JU; Hoffmann T; Schnider P; Stadler H; Koblet A; Alker A; Poli SM; Ballard TM; Spooren W; Steward L; Sleight AJ
Bioorg Med Chem Lett; 2010 Jun; 20(11):3405-8. PubMed ID: 20430616
[TBL] [Abstract][Full Text] [Related]
32. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor.
Salo OM; Raitio KH; Savinainen JR; Nevalainen T; Lahtela-Kakkonen M; Laitinen JT; Järvinen T; Poso A
J Med Chem; 2005 Nov; 48(23):7166-71. PubMed ID: 16279774
[TBL] [Abstract][Full Text] [Related]
33. Activity of cyclic pseudopeptide antagonists at peripheral tachykinin receptors.
Patacchini R; Quartara L; Astolfi M; Goso C; Giachetti A; Maggi CA
J Pharmacol Exp Ther; 1995 Mar; 272(3):1082-7. PubMed ID: 7891319
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.
Dawson LA; Langmead CJ; Dada A; Watson JM; Wu Z; de la Flor R; Jones GA; Cluderay JE; Southam E; Murkitt GS; Hill MD; Jones DN; Davies CH; Hagan JJ; Smith PW
Eur J Pharmacol; 2010 Feb; 627(1-3):106-14. PubMed ID: 19879867
[TBL] [Abstract][Full Text] [Related]
35. Novel NK(3) receptor antagonists for the treatment of schizophrenia and other CNS indications.
Simonsen KB; Juhl K; Steiniger-Brach B; Nielsen SM
Curr Opin Drug Discov Devel; 2010 Jul; 13(4):379-88. PubMed ID: 20597024
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist.
Ransom RW; Harrell CM; Reiss DR; Murphy KL; Chang RS; Hess JF; Miller PJ; O'Malley SS; Hey PJ; Kunapuli P; Su DS; Markowitz MK; Wallace MA; Raab CE; Jones AN; Dean DC; Pettibone DJ; Freidinger RM; Bock MG
Eur J Pharmacol; 2004 Sep; 499(1-2):77-84. PubMed ID: 15363953
[TBL] [Abstract][Full Text] [Related]
37. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
Miike T; Shirahase H; Kanda M; Kunishiro K; Kurahashi K
Vascul Pharmacol; 2009; 51(2-3):147-53. PubMed ID: 19539781
[TBL] [Abstract][Full Text] [Related]
38. N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.
Elliott JM; Carling RW; Chambers M; Chicchi GG; Hutson PH; Jones AB; MacLeod A; Marwood R; Meneses-Lorente G; Mezzogori E; Murray F; Rigby M; Royo I; Russell MG; Sohal B; Tsao KL; Williams B
Bioorg Med Chem Lett; 2006 Nov; 16(22):5748-51. PubMed ID: 16950620
[TBL] [Abstract][Full Text] [Related]
39. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Catarzi D; Varano F; Capelli F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Pedata F; Schiesaro A; Morizzo E; Moro S
J Med Chem; 2007 Aug; 50(17):4061-74. PubMed ID: 17665891
[TBL] [Abstract][Full Text] [Related]
40. Neurokinin-3 receptor-specific antagonists talnetant and osanetant show distinct mode of action in cellular Ca2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition.
Tian G; Wilkins D; Scott CW
Mol Pharmacol; 2007 Mar; 71(3):902-11. PubMed ID: 17172464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
